Targeting PP2A in cancer: Combination therapies

Area of Science:

• Molecular Biology
• Oncology
• Cancer Therapeutics

Background:

• Protein phosphatase 2A (PP2A) is a key regulator of the phosphoproteome, influencing critical cellular processes like apoptosis, proliferation, and DNA damage response.
• PP2A inactivation is a significant factor in cancer development and progression.
• The dual role of PP2A in cancer, acting as both a tumor suppressor and potentially a promoter, necessitates nuanced therapeutic strategies.

Purpose of the Study:

• To review existing studies on combination therapies involving PP2A-targeted agents in cancer treatment.
• To explore the therapeutic potential of both PP2A reactivation and inhibition in conjunction with other cancer treatments.
• To highlight emerging research on PP2A's role in tumor immunity.

Main Methods:

• Comprehensive literature review of preclinical and clinical studies.
• Analysis of research investigating PP2A reactivation combined with kinase inhibitors.
• Examination of studies exploring PP2A inhibition to enhance chemotherapy and radiotherapy efficacy.

Main Results:

• Combination therapies targeting PP2A demonstrate significant potential in counteracting oncogenic signaling and promoting cancer cell death.
• Both strategies—PP2A reactivation and inhibition—are being actively investigated across various cancer types.
• Preliminary findings suggest a role for PP2A modulation in influencing the tumor immune microenvironment.

Conclusions:

• Targeting PP2A offers a versatile therapeutic strategy in oncology, with applications in both tumor suppression and enhancing existing treatments.
• Further research into PP2A-based combination therapies is warranted to optimize treatment efficacy and explore novel applications, including immunotherapy.
• Understanding the complex role of PP2A in cancer biology is crucial for developing effective and personalized therapeutic approaches.